Stock TARA PROTARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Real-time Estimate Cboe BZX
Other stock markets
 11:46:21 2024-04-29 am EDT 		5-day change 1st Jan Change
2.88 USD -1.54% Intraday chart for Protara Therapeutics, Inc. -4.92% +54.66%
Apr. 22 Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26 MT
Apr. 05 Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition CI

Evolution of the average Target Price on Protara Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9f55f63e891c358de.EHs3wL5RwwKdS5JJwJttTK2liZwysTdM0o8QwurWaVo.ZjBSttRpu2bLMeE8rqs6dPziwOh9wWgZg9lKlIuJWQx9T0-y9TmwePwzyw~c1b03d9a346fef9800684e64082fc912

Analyst Recommendations on Protara Therapeutics, Inc.

Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26 MT
Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $30, Maintains Outperform Rating MT
Guggenheim Assumes Protara Therapeutics at Buy With $22 Price Target MT
HC Wainwright Cuts Protara Therapeutics' Price Target to $23 From $30, Maintains Buy Rating MT
Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $32, Maintains Outperform Rating MT
HC Wainwright Lowers Protara Therapeutics Price Target to $30 From $40, Buy Rating Kept MT
Oppenheimer Adjusts Protara Therapeutics Price Target to $32 From $34, Maintains Outperform Rating MT
Oppenheimer Adjusts Price Target on Protara Therapeutics to $34 from $32, Keeps Outperform Rating MT
PROTARA THERAPEUTICS : BofA Securities Starts Protara Therapeutics at Buy With $15 Price Target MT
PROTARA THERAPEUTICS : HC Wainwright Starts Protara Therapeutics at Buy With $40 Price Target MT
PROTARA THERAPEUTICS : Oppenheimer Adjusts Protara Therapeutics PT to $32 From $43, Maintains Outperform Rating MT
PROTARA THERAPEUTICS : Oppenheimer Initiates Coverage on Protara Therapeutics With Outperform Rating, $43 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.925 USD
Average target price
27.8 USD
Spread / Average Target
+850.43%
High Price Target
50 USD
Spread / Highest target
+1,609.40%
Low Price Target
14 USD
Spread / Lowest Target
+378.63%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Protara Therapeutics, Inc.

Oppenheimer
Guggenheim
HC Wainwright
BofA Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TARA Stock
  4. Consensus Protara Therapeutics, Inc.